Business description: Moderna, Inc.

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:

- revenue from product sales (97.4%);

- grant revenue (1.4%);

- revenue from collaboration agreements (1.2%).

At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development.

Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Number of employees: 5,800

Sales by Activity: Moderna, Inc.

Fiscal Period: December20202021202220232024

Biotechnology

803M 18.47B 19.26B 6.85B 3.24B
See all business segments

Geographical breakdown of sales: Moderna, Inc.

Fiscal Period: December20202021202220232024

United States

765M 6.18B 5.15B 1.9B 1.78B

Rest of World

38.87M 5.45B 7.3B 3.6B 853M

Europe

- 6.85B 6.82B 1.36B 598M
See all geographic segments

Executive Committee: Moderna, Inc.

Manager TitleAgeSince
Chief Executive Officer 52 2011-02-28
Director of Finance/CFO 48 2022-09-05
President 49 2024-10-31
Chief Tech/Sci/R&D Officer - 2022-12-31
Chief Tech/Sci/R&D Officer 53 2024-11-06
See MODERNA, INC. governance

Composition of the Board of Directors: Moderna, Inc.

Director TitleAgeSince
Director/Board Member 66 2018-05-31
Chairman 62 2012-01-31
Director/Board Member 52 2011-02-28
Director/Board Member 68 2019-12-10
Director/Board Member 76 2020-02-29
Director/Board Member 76 2020-06-30
Director/Board Member 73 2015-11-30
Director/Board Member 75 2024-08-04
Director/Board Member 60 2024-10-01
Composition of the Board of Directors

Shareholders: Moderna, Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.47 %
40,396,513 10.47 % 1 115 M $
Baillie Gifford & Co.
6.466 %
24,948,558 6.466 % 688 M $
5.513 %
21,269,463 5.513 % 587 M $
Fidelity Management & Research Co. LLC
5.477 %
21,130,029 5.477 % 583 M $
BlackRock Advisors LLC
5.395 %
20,813,245 5.395 % 574 M $
NameEquities%Valuation
BTG Pactual WM Gestão de Recursos Ltda.
0.000276 %
21,316 0.000276 % 29 018 $
List of MODERNA, INC. shareholders

Holdings: Moderna, Inc.

NameEquities%Valuation
1,707,473 4.56% 2,527,060 $
5,059,338 12.12% 1,973,142 $
5,859,375 8.77% 1,875,000 $

Company details: Moderna, Inc.

Moderna, Inc.

325 Binney Street

02142, Cambridge

+617 714 6500

http://www.modernatx.com
address Moderna, Inc.(MRNA)

Group companies: Moderna, Inc.

NameCategory and Sector
Biotechnology
Moderna Switzerland GmbH
See all subsidiaries

Biopharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
-1.87%+10.33%-72.61%-80.81% 13.01B
-0.61%-0.76%-20.24%-16.34% 76.69B
+1.43%+3.72%-47.44%-7.60% 59.99B
-2.13%+5.70%+29.69%+27.50% 54.72B
-0.96%+1.21%+18.22%+97.45% 37.99B
-0.83%+1.01%-43.32%-37.65% 19.67B
+0.37%-6.55%+110.04%+120.99% 17.54B
-2.23%+16.91%+62.89%+752.43% 17.06B
-0.04%-.--%+68.37%+138.03% 14.02B
-2.49%+0.20%+10.11%-15.28% 13.28B
Average -1.14%+1.92%+11.57%+97.87% 32.4B
Weighted average by Cap. -1.19%+1.52%+0.68%+56.80%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
33.64USD
Average target price
47.59USD
Spread / Average Target
+41.47%
Consensus

Quarterly revenue - Rate of surprise